公开(公告)号：EP3140648A2

公开(公告)日：2017-03-15

申请号：EP15789337.1

申请日：2015-05-11

申请人： The Trustees of Columbia University in the City of New York

发明人： CALIFANO, Andrea ,  BANSAL, Mukesh ,  SHIMONI, Yishai

IPC分类号： G01N33/48 ,  G01N33/50 ,  G06F17/00

CPC分类号： G06F19/702 ,  C40B30/02 ,  G06F19/12 ,  G06F19/24 ,  G06F19/703

摘要： Techniques to identify a mechanism of action of a compound using network dysregulation are disclosed herein. An example method can include selecting at least a first interaction involving at least a first gene, determining a first n-dimensional probability density of gene expression levels for the first gene and one or more genes in a control state, determining a second n-dimensional probability density of gene expression levels for the first gene and one or more genes following treatment using at least one compound, estimating changes between the first probability density and the second probability density, and determining whether the estimated changes are statistically significant.

摘要翻译： 技术来识别使用网络失调被盘在一个游离缺失化合物的作用的机构。 的示例性方法可以至少包括选择的第一交互至少涉及第一基因，确定性开采的第一个基因的基因表达水平和一个或更多个基因的一个控制状态的第一n维概率密度的，确定性的采矿第二n维 对于第一个基因的基因表达水平和一个或多个基因使用以下的至少一种化合物，无论是所估计的变化是统计学显著估计所述第一概率密度和第二概率密度，和确定性采矿之间的变化治疗概率密度。

公开(公告)号：EP2885429B1

公开(公告)日：2019-03-13

申请号：EP13829362.6

申请日：2013-08-16

申请人： The Trustees of Columbia University in the City of New York

发明人： ABATE-SHEN, Corrine ,  SHEN, Michael ,  CALIFANO, Andrea ,  KANTH, Shazia, Irshad ,  BANSAL, Mukesh

IPC分类号： C12Q1/6886 ,  G01N33/574

公开(公告)号：EP2885429A1

公开(公告)日：2015-06-24

申请号：EP13829362.6

申请日：2013-08-16

申请人： The Trustees of Columbia University in the City of New York

发明人： ABATE-SHEN, Corrine ,  SHEN, Michael ,  CALIFANO, Andrea ,  KANTH, Shazia, Irshad ,  BANSAL, Mukesh

IPC分类号： C12Q1/68 ,  G01N33/00

CPC分类号： G01N33/57434 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57415 ,  G01N33/57423 ,  G01N2333/4739 ,  G01N2333/50 ,  G01N2333/705 ,  G01N2333/71

摘要： A 3-gene prognostic panel has been identified that together accurately predicted the outcome of low Gleason score prostate tumors as either truly indolent or at a high risk of becoming aggressive. The 3-gene prognostic panel was validated on independent cohorts confirmed its independent prognostic value, as well as its ability to improve prognosis with currently used clinical nomograms. Expression of the 3-gene prognostic panel was determined by quantifying mRNA or protein encoded by the panel (collectively referred to as "prognostic biomarkers"). The prognostic biomarkers were discovered to be up-regulated in indolent tumors and down-regulated in aggressive forms of prostate cancer.